Centre d'evaluation et de traitement de la douleur, service de neurochirurgie, hôpital Salengro, CHU de Lille, 59037 Lille Cedex, France.
Rev Neurol (Paris). 2021 Sep;177(7):779-784. doi: 10.1016/j.neurol.2021.07.010. Epub 2021 Aug 9.
Around 15% to one-third of migraineurs experience aura. Aura is a fully reversible focal neurological phenomenon involving visual, sensory, speech, and/or motor symptoms that develops gradually and usually precedes the headache phase. The pivotal role of cortical spreading depression (CSD) as a mechanism underlying aura has been widely supported by a large body of studies. The diagnosis is based on the International Headache Classification Disorders III edition criteria. Aura is characterized by gradual development, duration of each symptom no longer than one hour, a mix of positive and negative features, and complete reversibility. Visual aura is the most common type of aura, occurring in over 90% of patients. When aura symptoms are multiple, they usually follow one another in succession, beginning with visual, then sensory, then aphasic; but the reverse and other orders have been noted. The accepted duration for most aura symptoms is one hour, but motor symptoms, which are rare, are often longer lasting. When a patient experiences for the first time a possible aura phase it's sometimes difficult to know if there was gradual or brutal onset of the symptoms. If the patient has no visual aura symptoms or simultaneous neurological symptoms, or presents neurological symptoms corresponding to a cerebral vascular territory, emergency exploration of a possible transient ischemic attack is necessary. Long duration (greater than one hour) of what may or may not be an aura phase, late onset of aura, or a dramatic increase in aura attacks should also be explored. The relative risk of ischemic stroke is significantly increased in migraine with aura. Combined hormonal contraception with estrogens significantly increases the risk of stroke in women with migraine with aura. It is recommended to start non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin as soon as possible during the aura phase, not to treat the aura, but to avoid or to diminish the headache phase. In case of failure of NSAIDs or aspirin it is recommended to use a triptan when the headache begins. The prophylactic treatments for migraine with aura are those used in migraine without aura based on very few randomized clinical trials specifically dedicated to migraine with aura.
大约 15%至 1/3 的偏头痛患者会出现先兆。先兆是一种完全可逆的局灶性神经现象,涉及视觉、感觉、言语和/或运动症状,逐渐发展,通常先于头痛期。皮质扩散性抑制 (CSD) 作为先兆潜在机制的核心作用已被大量研究广泛支持。该诊断基于国际头痛分类障碍第三版标准。先兆的特征是逐渐发展,每个症状的持续时间不超过 1 小时,阳性和阴性特征混合,完全可逆。视觉先兆是最常见的先兆类型,发生在超过 90%的患者中。当先兆症状多个时,它们通常一个接一个地相继出现,首先是视觉,然后是感觉,然后是失语;但也有记录到相反和其他顺序。大多数先兆症状的可接受持续时间为 1 小时,但罕见的运动症状通常持续时间更长。当患者首次出现可能的先兆期时,有时很难知道症状是逐渐还是突然发作。如果患者没有视觉先兆症状或同时出现神经系统症状,或出现与脑血管区域相对应的神经系统症状,则需要紧急探索可能的短暂性脑缺血发作。持续时间长(大于 1 小时)的可能是或可能不是先兆期、先兆期迟发或先兆发作急剧增加也应进行探索。有先兆偏头痛患者发生缺血性中风的相对风险显著增加。含有雌激素的联合激素避孕显著增加了有先兆偏头痛女性中风的风险。建议在先兆期尽快开始使用非甾体抗炎药 (NSAIDs) 或阿司匹林,而不是治疗先兆,而是避免或减轻头痛期。如果 NSAIDs 或阿司匹林治疗失败,建议在头痛开始时使用曲坦类药物。基于专门针对有先兆偏头痛的极少数随机临床试验,有先兆偏头痛的预防性治疗与无先兆偏头痛相同。